Id: acc4798
Group: 1sens
Protein: IkappaB
Gene Symbol: NFKBIA
Protein Id: P25963
Protein Name: IKBA_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Immune system diseases
Disease: Atopic Dermatitis
Disease Subtype:
Disease Cellline: HaCaT?
Disease Info:
Drug: Rosa davurica Pall.
Drug Info: Rosa davurica Pall. is a type of plant that may have certain pharmacological properties and is used in traditional medicine.
Effect: modulate
Effect Info: "RDL pretreatment inhibits the activation of NF-κB by reducing p-IκB and p-NF-κB, thereby suppressing the inflammatory response."
Note:
Score: 4.0
Pubmed(PMID): 34455178
Sentence Index:
Sentence:

Sequence & Structure:

MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - N Autosomal dominant anhidrotic ectodermal dysplasia Phosphorylation 14523047
- - U Colorectal cancer Ubiquitination 31685801
- - U Squamous cell carcinoma Ubiquitination 35128752

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: